Atria Wealth Solutions’s Viking Therapeutics VKTX Stock Holding History

Atria Wealth Solutions’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,352	Closed	-$212K	–	2098
2024 Q3	$212K	Buy	+3,352	New	+$197K	﹤0.01%	1750

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Atria Wealth Solutions's VKTX Position: Q4 2024 in Review

Atria Wealth Solutions sold out of Viking Therapeutics (VKTX) in Q4 2024, closing a stake of 3,352 shares — an estimated $212K sold.

Atria Wealth Solutions first reported a position in VKTX in Q3 2024 and held it in 1 quarter. The position peaked at $212K in Q3 2024. 408 funds tracked by Wall St. Rank hold VKTX as of Q4 2024.

Atria Wealth Solutions reported no remaining Viking Therapeutics position as of Q4 2024 after selling out during the quarter.
Atria Wealth Solutions sold 3,352 Viking Therapeutics shares in Q4 2024, an estimated $212K.
Atria Wealth Solutions first reported a position in Viking Therapeutics in Q3 2024 and held it in 1 quarter.
Atria Wealth Solutions's Viking Therapeutics position peaked at $212K in Q3 2024.
408 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2024.

Based on Atria Wealth Solutions's 13F filing for Q4 2024, filed 31 Jan 2025.